In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity.

@article{Btry2011InVE,
  title={In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity.},
  author={C{\'e}cile B{\'e}try and Adeline Eti{\'e}vant and Laura Lamb{\'a}s-Se{\~n}as and Andrew C McCreary and Nasser Haddjeri},
  journal={Synapse},
  year={2011},
  volume={65 10},
  pages={1042-51}
}
The nonergot ligand pardoprunox (SLV308) is a dopamine (DA) D₂/D₃ and serotonin (5-HT)(1A) receptor agonist and a new candidate for the treatment of Parkinson's disease. We used in vivo electrophysiological paradigm in the rat to assess the effects of pardoprunox on DA neuronal activity in ventral tegmental area (VTA) and substantia nigra pars compacta (SNc… CONTINUE READING